GlaxoSmithKline (GSK) is embroiled in a lawsuit filed by an independent Connecticut laboratory, Valisure, which accuses the drugmaker of defrauding the U.S. gov

GSK Faces Lawsuit Over Alleged Concealment of Zantac Cancer Risks


blog post cover photo

Image credit: Hal Gatewood

GlaxoSmithKline (GSK) is embroiled in a lawsuit filed by an independent Connecticut laboratory, Valisure, which accuses the drugmaker of defrauding the U.S. government and taxpayers by concealing cancer risks associated with Zantac, a once-popular heartburn drug.

In the whistleblower complaint filed on Monday, Valisure alleges that GSK violated the federal False Claims Act by hiding the risks of Zantac for nearly four decades, while Medicare, Medicaid, and other health programs covered billions of dollars of prescriptions.

According to Valisure, its testing in 2019 revealed that Zantac, also known as ranitidine, could form a cancer-causing carcinogen called NMDA, rendering it "unfit for human consumption." The lab claims that GSK concealed this information from the U.S. Food and Drug Administration (FDA), which approved Zantac in 1983.

Valisure is seeking billions of dollars in damages from GSK, including civil fines of up to $11,000 per violation, in a complaint filed in Philadelphia, where some of the British drugmaker's operations are based. The lab's lawyers also represent thousands of plaintiffs in personal injury lawsuits against GSK and other companies that have sold ranitidine.

In response, GSK stated that it would defend against Valisure's "meritless" lawsuit, emphasizing that the FDA has found the lab's tests "scientifically flawed and unreliable." GSK maintains that there is no consistent or reliable evidence that ranitidine increases cancer risks.

Stay informed about legal developments and industry news by accessing the Trending Social Sentiment API: Link

Other Blogs

Nov 25, 2023 6:39 AM - Parth Sanghvi

DCF Valuation vs. Comparable Companies Analysis: Choosing the Right Valuation Method

Choosing the Right Valuation Method: DCF vs. Comparable Companies Analysis Introduction: Valuation methods play a pivotal role in determining the fair value of a company, aiding investors in making informed investment decisions. Two commonly used methods, DCF Valuation and Comparable Companies A...

blog post title

Dec 23, 2023 2:19 AM - Parth Sanghvi

Understanding the Limitations of DCF Analysis: A Guide to Overcoming Challenges

Introduction: Discounted Cash Flow (DCF) analysis stands as a cornerstone in valuing investments, yet its efficacy is contingent upon various assumptions and methodologies. While a powerful tool, DCF analysis comes with inherent limitations and challenges that investors must acknowledge to make i...

blog post title

Dec 25, 2023 2:28 AM - Parth Sanghvi

Integrating Sustainability into Valuations: Navigating ESG Factors within the Discounted Cash Flow (DCF) Model

Introduction: The investment landscape is undergoing a profound shift with a heightened emphasis on sustainability and responsible investing. In this blog post, we explore the intersection of Environmental, Social, and Governance (ESG) considerations within the Discounted Cash Flow (DCF) model, h...

blog post title


Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
2017-2024 © Financial Modeling Prep